Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn
Rattachement africain : us, fr, ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Aims Metabolic syndrome (MetSyn) is associated with high risk of cardiovascular (CV) events, irrespective of statin therapy. In the overall REDUCE-IT study of statin-treated patients, icosapent ethyl (IPE) reduced the risk of the primary composite endpoint (CV death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or unstable angina requiring hospitalization) and the key secondary composite endpoint (CV death, non-fatal myocardial infarction, or non-fatal stroke). Methods and results REDUCE-IT was an international, double-blind trial that randomized 8179 high CV risk statin-treated patients with controlled LDL cholesterol and elevated triglycerides to IPE 4 g/day or placebo. The current study evaluated the pre-specified patient subgroup with a history of MetSyn, but without diabetes at baseline. Among patients with MetSyn but without diabetes at baseline (n = 2866), the majority (99.8%) of this subgroup was secondary prevention patients. Icosapent ethyl use was associated with a 29% relative risk reduction for the first occurrence of the primary composite endpoint [hazard ratio: 0.71; 95% confidence interval (CI): 0.59–0.84; P < 0.0001, absolute risk reduction (ARR) = 5.9%; number needed to treat = 17] and a 41% reduction in total (first plus subsequent) events [rate ratio: 0.59; (95% CI: 0.48–0.72); P < 0.0001] compared with placebo. The risk for the key secondary composite endpoint was reduced by 20% (P = 0.05) and a 27% reduction in fatal/non-fatal MI (P = 0.03), 47% reduction in urgent/emergent revascularization (P < 0.0001), and 58% reduction in hospitalization for unstable angina (P < 0.0001). Non-statistically significant reductions were observed in cardiac arrest (44%) and sudden cardiac death (34%). Conclusion In statin-treated patients with a history of MetSyn, IPE significantly reduced the risk of first and total CV events in REDUCE-IT. The large relative and ARRs observed supports IPE as a potential therapeutic consideration for patients with MetSyn at high CV risk. Registration REDUCE-IT ClinicalTrials.gov number: NCT01492361
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn
- Date Crossref
- 01/11/2023
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hospital of the University of Pennsylvania Department of Medicine pays non établi dans la noticeÉtablissement de santé
-
Mount Sinai Hospital pays non établi dans la noticeÉtablissement de santé
-
Icahn School of Medicine at Mount Sinai Mount Sinai Fuster Heart Hospital pays non établi dans la noticeUniversité ou école supérieure
-
Louisville Metabolic and Atherosclerosis Research Center pays non établi dans la noticeStructure de recherche
-
Emory University Lipid Clinic and Cardiovascular Risk Reduction Program pays non établi dans la noticeUniversité ou école supérieure
-
Inserm pays non établi dans la noticeOrganisme public
-
Université Paris Cité pays non établi dans la noticeUniversité ou école supérieure
-
Assistance Publique – Hôpitaux de Paris pays non établi dans la noticeÉtablissement de santé
-
Hôpital Bichat-Claude-Bernard pays non établi dans la noticeÉtablissement de santé
-
Amarin (United States) pays non établi dans la noticeEntreprise
-
Montreal Heart Institute pays non établi dans la noticeOrganisme public
-
Université de Montréal Montreal Heart Institute pays non établi dans la noticeUniversité ou école supérieure
Department of Medicine — Hospital of the University of Pennsylvania, Mount Sinai Hospital et Mount Sinai Fuster Heart Hospital — Icahn School of Medicine at Mount Sinai, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.